Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.47 |
| ▸ | GPR3 | P46089 | 1/20 | 0.41 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.41 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.41 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.41 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 4/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22308330 | 0.85 | KDM4E (0.46) | KDM4ESSTR4GPR3MAPK13EIF2AK2 | |
| SCHEMBL12535857 | 0.85 | KDM4E (0.50) | KDM4ESSTR4GPR3MAPK13EIF2AK2 | |
| SCHEMBL16256140 | 0.85 | KDM4E (0.46) | KDM4ESSTR4GPR3MAPK13EIF2AK2 | |
| SCHEMBL20458071 | 0.82 | KDM4E (0.44) | KDM4ESSTR4GPR3MAPK13EIF2AK2 | |
| SCHEMBL19954900 | 0.79 | KDM4E (0.42) | KDM4ESSTR4GPR3MAPK13EIF2AK2 | |
| SCHEMBL28848043 | 0.78 | TSHR (0.38) | KDM4ESSTR4GPR3ADORA1ADORA3 | |
| SCHEMBL14158377 | 0.78 | PDE5A (0.41) | KDM4ESSTR4GPR3CNR2ADORA1 | |
| SCHEMBL13708517 | 0.78 | MPO (0.42) | SSTR4ADORA1ALDH1A1CYP3A4TSHR | |
| SCHEMBL18346735 | 0.77 | LMNA (0.60) | ALDH1A1MEN1CYP2D6KMT2ALMNA | |
| SCHEMBL12535855 | 0.77 | KDM4E (0.43) | KDM4ESSTR4GPR3MAPK13EIF2AK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 188 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238423-A9 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. | 2024-07-18 | — | — | US | disclosed |
| US-20240208967-A1 | Pyrimidine or Pyridine Compounds, Preparation Method Therefor and Pharmaceutical Uses Thereof | INVENTISBIO CO LTD (CN) | 2024-06-27 | — | — | US | disclosed |
| US-12018045-B2 | 17-beta-hydroxywithanolides and use thereof in treating cancer | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-06-25 | — | — | US | disclosed |
| US-12018045-B2 | 17-beta-hydroxywithanolides and use thereof in treating cancer | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-06-25 | — | — | US | disclosed |
| WO-2024081311-A1 | CBL-B MODULATORS AND USES THEREOF | NIMBUS CLIO, INC. (US) | 2024-04-18 | — | — | WO | disclosed |
| WO-2023215482-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. (US) | 2023-11-09 | — | — | WO | disclosed |
| US-20230339980-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | AGIOS PHARMACEUTICALS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230339980-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | AGIOS PHARMACEUTICALS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-11787780-B2 | Quaternary indazole glucocorticoid receptor antagonists | CORCEPT THERAPEUTICS INCORPORATED (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787780-B2 | Quaternary indazole glucocorticoid receptor antagonists | CORCEPT THERAPEUTICS INCORPORATED (US) | 2023-10-17 | — | — | US | disclosed |
| US-20100256210-A1 | METHODS AND COMPOSITIONS FOR DELIVERING 5-HT3 ANTAGONISTS ACROSS THE ORAL MUCOSA | TRANSORAL PHARMACEUTICALS, INC. | 2010-10-07 | — | — | US | disclosed |
| US-7790743-B2 | Modulators of cellular adhesion | SARCODE CORPORATION (US) | 2010-09-07 | — | — | US | disclosed |
| US-7745460-B2 | Modulators of cellular adhesion | SARCODE CORPORATION (US) | 2010-06-29 | — | — | US | disclosed |
| US-20100093693-A1 | MODULATORS OF CELLULAR ADHESION | BAUSCH + LOMB IRELAND LIMITED (IE) | 2010-04-15 | — | — | US | disclosed |
| US-20090137614-A1 | Pharmaceutical combination comprising vitamin k | SHIONOGI & CO., LTD. (JP) | 2009-05-28 | — | — | US | disclosed |
| US-20080213363-A1 | Ionized form capable of being converted into an un-ionized form; and buffer system changes the pH of saliva from an arbitrary initial pH to a predetermined final pH; sodium carbonate and sodium bicarbonate; acetic acid and sodium acetate; lozenge, chewing gum, dissolving tablet | TRANSORAL PHARMACEUTICALS, INC. | 2008-09-04 | — | — | US | disclosed |
| US-20080182839-A1 | MODULATORS OF CELLULAR ADHESION | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-07-31 | — | — | US | disclosed |
| US-20080176896-A1 | Modulators of cellular adhesion | BAUSCH + LOMB IRELAND LIMITED (IE) | 2008-07-24 | — | — | US | disclosed |
| US-7314938-B2 | Immune and/or inflammatory disorders; autoimmune disorders; disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1); antagonize CD11/CD18 receptors associated with leukocytes. | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-01-01 | — | — | US | disclosed |
| US-7223785-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787780-B2 | Quaternary indazole glucocorticoid receptor antagonists | NR3C1, NR3C2, MC2R | KDM4E 3007/4885SSTR4 321/4885GPR3 116/4885 |
| US-20080176896-A1 | Modulators of cellular adhesion | ITGB1, VCAM1, ITGB8 | KDM4E 3313/4885SSTR4 3719/4885GPR3 523/4885 |
| US-20090137614-A1 | Pharmaceutical combination comprising vitamin k | PPARD, PROC, VDR | KDM4E 2655/4885SSTR4 4793/4885GPR3 518/4885 |
| US-20240208967-A1 | Pyrimidine or Pyridine Compounds, Preparation Method Therefor and Pharmaceutical Uses Thereof | EGFR, WEE1, DPYD | KDM4E 2722/4885SSTR4 2503/4885GPR3 1691/4885 |
| US-12018045-B2 | 17-beta-hydroxywithanolides and use thereof in treating cancer | HSD17B7, CYP17A1, HSD17B11 | KDM4E 3479/4885SSTR4 3524/4885GPR3 1215/4885 |
| US-20100093693-A1 | MODULATORS OF CELLULAR ADHESION | ITGB1, VCAM1, ITGB8 | KDM4E 3304/4885SSTR4 3716/4885GPR3 524/4885 |
| US-20230339980-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | PAH, KDM8, PHF8 | KDM4E 104/4885SSTR4 4003/4885GPR3 1484/4885 |
| US-20240238423-A9 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | BCL2A1, BCL2L1, BCL3 | KDM4E 1040/4885SSTR4 4028/4885GPR3 1193/4885 |
| US-20080213363-A1 | Ionized form capable of being converted into an un-ionized form; and buffer system changes the pH of saliva from an arbitrary initial pH to a predetermined final pH; sodium carbonate and sodium bicarbonate; acetic acid and sodium acetate; lozenge, chewing gum, dissolving tablet | SI, HTR3A, GALR3 | KDM4E 3527/4885SSTR4 1164/4885GPR3 43/4885 |
| US-20080182839-A1 | MODULATORS OF CELLULAR ADHESION | ITGB1, VCAM1, ITGB8 | KDM4E 3330/4885SSTR4 3725/4885GPR3 520/4885 |
| US-20100256210-A1 | METHODS AND COMPOSITIONS FOR DELIVERING 5-HT3 ANTAGONISTS ACROSS THE ORAL MUCOSA | SLC9A3, HTR3A, HTR3C | KDM4E 4184/4885SSTR4 255/4885GPR3 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.